Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial - Wikidata - wikimedia - TriplyDB

Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial

Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial

http://www.wikidata.org/entity/Q37152501

about

Early versus delayed erythropoietin for the anaemia of end-stage kidney disease Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients.Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST)Cardiac biomarkers and health-related quality of life in new hemodialysis patients without symptomatic cardiac disease.Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia Use of agents stimulating erythropoiesis in digestive diseases Quality of life measures predict cardiovascular health and physical performance in chronic renal failure patients.Psychosocial and Clinical Correlates of Fatigue in Haemodialysis Patients: the Importance of Patients' Illness Cognitions and Behaviours.Treatment of confirmed B12 deficiency in hemodialysis patients improves Epogen® requirements.Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients.Determination of the relationship between adequacy of dialysis and quality of life and self-care agency.Change in quality of life and one-year mortality risk in maintenance dialysis patients.Self-perceived quality of sleep and mortality in Norwegian dialysis patients.Nutritional status evaluated by multi-frequency bioimpedance is not associated with quality of life or depressive symptoms in hemodialysis patients.Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.Association Between Anemia and Fatigue in Hospitalized Patients: Does the Measure of Anemia Matter?

P2860

Q24187089-A08D8A9F-F4F5-48B3-88BF-B93D5952CDD7 Q24187413-46AC242C-89CA-4DD9-BBA7-47FB64A44EA9 Q24194545-AD749A0D-183A-44A6-877F-550B92237EA0 Q28468446-0F13B207-B9E2-4848-9BA5-818136F8AFC9 Q34534923-F392A41D-89EB-495E-B1B9-B61D5394F6FD Q35151878-9D05CF0A-6D80-4C6C-AE46-411B814D2D6E Q35674143-66ACE5FD-83F7-4103-96EE-E8C9C554D16B Q36746039-8C573F4E-E8CF-43F3-8A1C-4B543C18C4DC Q37368733-AB102120-D823-403F-A4C5-E1DB7C468B69 Q40041287-106FA2C0-60D4-4B0D-A685-2F42AE055A09 Q40274929-66B36859-A6EE-490A-A8BF-28C345FF4B62 Q41858575-23CFC9DA-EC4D-4C43-8443-8259951D45C6 Q42364444-AE81E177-A279-4267-A8B7-43E0A97E1A19 Q45844567-27E7AC48-A113-4021-BBE6-4E00D98DA3D2 Q47807405-E413F67F-36AD-4199-BB0E-63647D378561 Q48166701-4C4726B7-8304-4827-A652-16308D6928A6 Q48703205-D4F505BB-3DF6-4277-ADCB-59EEF52D3A5F Q51546144-B466474F-AB05-4319-AAF5-847B90E6D69D Q53091807-6A8C5463-13A2-42F3-B9CA-94D5EE20CD16

P2860

Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial

http://www.wikidata.org/entity/Q37152501

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Erythropoietin therapy, hemogl ...... s patients: a randomized trial

@en

Erythropoietin therapy, hemogl ...... patients: a randomized trial.

@nl

type

label

Erythropoietin therapy, hemogl ...... s patients: a randomized trial

@en

Erythropoietin therapy, hemogl ...... patients: a randomized trial.

@nl

prefLabel

Erythropoietin therapy, hemogl ...... s patients: a randomized trial

@en

Erythropoietin therapy, hemogl ...... patients: a randomized trial.

@nl

P1433

Q37152501-C117F452-02AF-41D1-865F-B3B1455606D0

P1476

Q37152501-1382D488-F64D-4436-ACF1-D0B19AA0CA55

P2093

Q37152501-254BFBA2-E4F1-422C-98DF-1B8C75202D5F

Q37152501-266A9A22-9E20-4FCF-AC66-20340D0EC970

Q37152501-41857871-34F5-47A7-99EB-BDB1967AEEC5

P2860

Q37152501-1BA9C137-D8C4-406B-BF87-A3B52B50FA9F

Q37152501-21643010-1E2E-4C42-86CC-840A9AE30F5E

Q37152501-22DA5155-F5FF-4C9B-9501-40A95D55821C

Q37152501-32081613-6FA7-4B12-94E3-6E114B1FC0F1

Q37152501-5518536C-DFC5-4A7A-86B8-BBE452DD8572

Q37152501-9CC2D232-E4CC-4661-81A0-41D9DF4E3935

Q37152501-A3183BA1-4B89-4181-8DE2-96E49C439CA5

Q37152501-CD8A8571-FE61-4955-86E9-CD7BC4DDEE56

Q37152501-D3139D8A-7AFD-4A23-93C0-00019E970F70

Q37152501-E0276657-C225-4B26-AD26-87E929430579

P304

Q37152501-C8DDDEB7-6334-41A8-8EFF-775F3ADAA7E4

P31

Q37152501-8704E006-2E3D-4A8D-BA57-F304C3DDD5FE

P356

Q37152501-A8D0AB83-EBA3-407F-86F6-51C17C80CA2D

P433

Q37152501-1B38AB85-73BE-45D9-9173-39D7EEDB9C71

P478

Q37152501-091741C7-798D-4FFC-A6D6-3B3AB01438C3

P577

Q37152501-628750DF-B557-4910-9FF2-AD16DEC3395F

P5875

Q37152501-3168469E-D8E7-44BD-AF23-BDD2BA8CEB97

P698

Q37152501-2DF01026-AEEE-4579-842C-9779A1C2BA9D

P921

Q37152501-19E8B9E8-6084-41FD-AC21-AE072006DA1C

Q37152501-DFC4C524-6832-4C14-83B8-39BADB832F7D

P932

Q37152501-D62F3E1B-A0BB-4CAA-A6DB-B057D272C9C3

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Erythropoietin therapy, hemogl ...... s patients: a randomized trial

@en

P2093

Bryan M Curtis

http://www.w3.org/2001/XMLSchema#string

Patrick S Parfrey

http://www.w3.org/2001/XMLSchema#string

Robert N Foley

http://www.w3.org/2001/XMLSchema#string

P2860

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Development of the kidney disease quality of life (KDQOL) instrument.

Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.

Erythropoietin therapy.

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients.

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.

Comparative mortality of hemodialysis and peritoneal dialysis in Canada.

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

P304

726-733

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.04950908

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24251099

http://www.w3.org/2001/XMLSchema#string

P698

19339412

http://www.w3.org/2001/XMLSchema#string

P921

quality of life

P932

2666430

http://www.w3.org/2001/XMLSchema#string